[HTML][HTML] Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities

ED Mock, B Gagestein, M van der Stelt - Progress in Lipid Research, 2023 - Elsevier
Abstract N-acylethanolamines (NAEs), including N-palmitoylethanolamine (PEA), N-
oleoylethanolamine (OEA), N-arachidonoylethanolamine (AEA, anandamide), N …

[HTML][HTML] Cirrhotic cardiomyopathy

L Ruiz-del-Árbol, R Serradilla - World journal of gastroenterology, 2015 - ncbi.nlm.nih.gov
During the course of cirrhosis, there is a progressive deterioration of cardiac function
manifested by the disappearance of the hyperdynamic circulation due to a failure in heart …

New developments on the treatment of liver fibrosis

Y Koyama, J Xu, X Liu, DA Brenner - Digestive diseases, 2016 - karger.com
Liver fibrosis results from many chronic injuries and often progresses to cirrhosis, liver
failure, portal hypertension, and hepatocellular carcinoma. Liver transplantation is the only …

Cirrhotic cardiomyopathy: review of pathophysiology and treatment

M Chayanupatkul, S Liangpunsakul - Hepatology international, 2014 - Springer
Cirrhotic cardiomyopathy is a cardiac condition observed in patients with cirrhotic regardless
of the etiologies. It is characterized by the impaired systolic response to physical stress …

Medicinal Chemistry, Pharmacology, and Potential Therapeutic Benefits of Cannabinoid CB2 Receptor Agonists

M Aghazadeh Tabrizi, PG Baraldi, PA Borea… - Chemical …, 2016 - ACS Publications
The endocannabinoid system is represented by a group of neuromodulatory lipids and their
receptors that are involved in a variety of physiological and pathological conditions. The …

Endocannabinoid system in hepatic glucose metabolism, fatty liver disease, and cirrhosis

I Bazwinsky-Wutschke, A Zipprich… - International Journal of …, 2019 - mdpi.com
There is growing evidence that glucose metabolism in the liver is in part under the control of
the endocannabinoid system (ECS) which is also supported by its presence in this organ …

Role of cannabis and its derivatives in gastrointestinal and hepatic disease

J Gotfried, T Naftali, R Schey - Gastroenterology, 2020 - Elsevier
Medical and recreational cannabis use has increased dramatically over the last decade,
resulting from mainstream cultural acceptance and legalization in several countries …

Cannabinoids and chronic liver diseases

RS Mboumba Bouassa, G Sebastiani… - International Journal of …, 2022 - mdpi.com
Nonalcoholic fatty liver disease (NAFLD), alcohol-induced liver disease (ALD), and viral
hepatitis are the main causes of morbidity and mortality related to chronic liver diseases …

New aspects of hepatic endothelial cells in physiology and nonalcoholic fatty liver disease

X Sun, EN Harris - American Journal of Physiology-Cell …, 2020 - journals.physiology.org
The liver is the central metabolic hub for carbohydrate, lipid, and protein metabolism. It is
composed of four major types of cells, including hepatocytes, endothelial cells (ECs), Kupffer …

The endocannabinoid system and cannabidiol: Past, present, and prospective for cardiovascular diseases

M Rabino, S Mallia, E Castiglioni, D Rovina… - Pharmaceuticals, 2021 - mdpi.com
In the past, cannabis was commonly associated with mysticism and illegality. Fortunately, in
recent years perspectives and discourses have changed. More prominence has been given …